Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Rt.

Onp Holdings Se

Egis Gyogyszergyar Zrt.

Kálmán Nagy

Györgyi Vereczkeyné Donáth

Gyula Simig

Tibor Mezei

Márta Porcs-Makkay

Gyuláné Körtvélyessy

József Barkóczy

Ferenc Lorant Bartha

Balázs Volk

Péter Trinka

Zsuzsanna Szent-Királlyi

Tamás Gregor

László Pongó

József Reiter

Zoltán Katona

György Clementis

Zoltán Varga

Gyula Lukacs

László Szlávik

Gábor Németh

Endre Mikulásik

Adrienn Keszthelyi

Gyula Lukács

Péter Kótay Nagy

Enikó Molnár

Tamás Spaits

Gábor Berecz

Bálint Nyulasi

András Mravik

János Szulágyi

Éva Pécsi

Norbert Nemeth

Norbert Mesterházy

Imre Markovits

Judit Broda

Imre Kapui

Angéla Pandur

Krisztina Fodorné Kocsmár

György Krasznay

Gábor Attila Bacher

Enikö Molnar

Györgyi Vereczekeyné Donath

Lászlö Pongo

Zsuzsanna Évinger

Enikö Molnár

Béla Farkas

György Ruzsics

Péter Slégel

László Koncz

Györgyi Vereczkeyne Donath

Györgyi Kovanyine Lax

Gábor Nemeth

Beatrix Bánkövi

Gitta Kiss

Ottó Albrecht

Réka Eszter Puskás

Gyöngyi Heréb

Máté Hudák

Tamás Mórász

Livia Gregorné Boros

Valéria Hofmanné Fekete

György Krasznai

József Debreczeni

Gyuláné Körtvelyessy

Péter Kotay Nagy

József Barkoczy

Enikõ Molnár

Donáth Györgyi Vereczkeyné

Gyorgyi Vereczkeyn Donáth

Judit Cselenyak

Imre KÖHEGYI

János Imre

Valéria HoffmannÉ Fekete

Feren Bartha

Jozsef BARKÓCZY

Endre MIKULÁSIK

György MOROVJÁN

Györgyi KOVÁNYINÉ Lax

András DancsÓ

The object of the present invention is a process for preparing the 2-acetoxi-5-(2-fluor-&#x3b1;-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-thieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts from crystalline 5-trityl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof.

Process for preparing pharmaceutical compounds and intermediate compounds

A method for purifying diatomaceous earth, whose natural colloidal structure is retained, which includes preparing a suspension of diatomaceous earth in a liquid wherein diatomaceous earth is insoluble, separating diatomaceous earth from the suspension, treating diatomaceous earth with an inorganic or organic acid, heat-treating the thus obtained product at a temperature not higher than 300&#xb0; C., subjecting the product obtained to oxidative treatment and drying the purified product.

Method for purifying diatomaceous earth

According to the present invention, 2-chloroethoxy-acetic acid-N,N-dimethylamide of the Formula (I) is prepared by reacting 2-hydroxyethoxy-acetic acid-N,N-dimethylamide of the Formula (II) in a solvent optionally in the presence of a catalyst with thionyl chloride and removing the solvent by distillation. 

[object Object]

The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium sait monohydrate is produced. Said sait is subsequently treated with mineral or organic acid to yield high-purity meloxicam.

Process for preparation of high-purity meloxicam and meloxicam potassium salt

The invention relates to a process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno-[2,3-b][1,5]benzodiazepine (olanzapine) of the formula (I) by reacting 4-amino-2-methyl-10H-thieno[2,3-b][1/5]benzodiazepine hydrochloride of the formula (II) with N-methylpiperazine in an organic solvent, which comprises carrying out the reaction in the mixture of toluene and 1,3-dimethyl-2-imidazolidinone. The invention also encompasses new 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b] [1,5]benzodiazepine dihydrochloride trihydrate of the formula (IB), the preparation thereof and pharmaceutical compositions comprising said new compound. 

Process for the preparation of olanzapine

The present invention is related to 1-[(4-chlorophenyl)-phenylmethyl]-4-(2,2,2-trichloroethoxycarbonyl)-piperazine of the Formula (IV) and optically isomers thereof, process for preparation thereof and the use of the compound of the Formula (IV) in the preparation of 1-(4-chlorophenyl)-phenylmethyl-piperazine and optical isomers and salts thereof. 1-(4-chlorophenyl)-phenylmethyl-piperazine and optical isomers thereof are important intermediates in the preparation of non-sedating antihistamine-type active pharmaceutical ingredients. 

Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates

The present invention relates to a new method of preparation of the polymorph form 1 of methyl (S)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl-acetate hydrogensulfate of the formula (I) 

Process for the preparation of amorphous form of a platelet aggregation inhibitor drug

The invention relates to a process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one of the Formula (I), and pharmaceutically acceptable acid addition salts thereof by subjecting the oxime of the Formula (II), to ring-closure in the presence of an alkali hydroxide, alkali carbonate or alkali-Calkoxide in an inert organic solvent, converting the base of the Formula I thus obtained into an acid addition salt or setting free the base of the Formula I from an acid addition salt thereof which comprises reacting a halogen derivative of the general Formula (XIV), (wherein Hal is halogen) with piperidine oxime derivative of the Formula (V), or an acid addition salt thereof in the presence of a base, and using by the ring-closure of the oxime of the Formula II formed a C-alkanol as inert solvent. The process of the present invention enables the economical preparation of a product having a purity suitable for pharmaceutical purposes.

Process for the preparation of 3-{2-'4- (6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyllethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido&#x2032;1,2-methyl-4h-pyrido&#x2032;,2-a!pyrimidin-4-one

Growing community of inventors

Budapest, Hungary

Kálmán Nagy